South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - tablet - see ingredients - each tablet contains furosemide 40 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; silicon dioxide; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - chlortalidone, quantity: 25 mg - tablet, uncoated - excipient ingredients: purified talc; iron oxide yellow; iron oxide red; colloidal anhydrous silica; lactose monohydrate; maize starch; magnesium stearate - indications as at 19 november 1996: essential arterial hypertension, as long as creatinine clearance is >30 ml/min; as primary therapy or in combination with other antihypertensive agents; stable, chronic heart failure of mild to moderate degree (functional class ii, iii), as long as creatinine clearance is >30ml/min; ascites due to cirrhosis of the liver in stable patients under close control.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - indapamide hemihydrate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; magnesium stearate; hypromellose; sodium lauryl sulfate; titanium dioxide; indigo carmine; iron oxide red; erythrosine; macrogol 400 - management of essential hypertension. it may be tried as the sole therapeutic agent in the treatment of mild to moderate hypertension. normally indapamide is used as the initial agent in multiple drug regimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - penicillamine, quantity: 250 mg - tablet, film coated - excipient ingredients: povidone; stearic acid; microcrystalline cellulose; titanium dioxide; glycerol; hypromellose; sodium starch glycollate - severe, active rheumatoid arthritis. as a chelating agent in the treatment of wilson's disease and lead poisoning. d-penamine will enhance urinary excretion of gold and mercury and other heavy metals. in the treatment of cysturia in cases where high-fluid regimens are not adequate, or in conjunction with them.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - penicillamine, quantity: 125 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; glycerol; titanium dioxide; hypromellose; stearic acid; sodium starch glycollate - severe, active rheumatoid arthritis. as a chelating agent in the treatment of wilson's disease and lead poisoning. d-penamine will enhance urinary excretion of gold and mercury and other heavy metals. in the treatment of cysturia in cases where high-fluid regimens are not adequate, or in conjunction with them.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg; indapamide hemihydrate, quantity: 1.25 mg (equivalent: indapamide, qty 1.22 mg) - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hydrophobic colloidal silica anhydrous; magnesium stearate - treatment of hypertension. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - indapamide hemihydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: titanium dioxide; macrogol 6000; hypromellose; lactose monohydrate; magnesium stearate; colloidal anhydrous silica; glycerol; povidone - treatment of hypertension. it may be tried as a sole therapeutic agent in the treatment of hypertension. normally, ardix indapamide sr is used as the initial agent in multiple drug regimes.